stoxline Quote Chart Rank Option Currency Glossary
  
Penumbra, Inc. (PEN)
193.66  2.97 (1.56%)    05-24 16:00
Open: 190.96
High: 196.25
Volume: 185,195
  
Pre. Close: 190.69
Low: 190.96
Market Cap: 7,507(M)
Technical analysis
2024-05-27 4:48:12 PM
Short term     
Mid term     
Targets 6-month :  244.12 1-year :  257.43
Resists First :  209.01 Second :  220.4
Pivot price 203.64
Supports First :  190.58 Second :  158.56
MAs MA(5) :  196.99 MA(20) :  203.65
MA(100) :  231.54 MA(250) :  249.43
MACD MACD :  -4.6 Signal :  -3.9
%K %D K(14,3) :  4.3 D(3) :  7.8
RSI RSI(14): 37.5
52-week High :  348.67 Low :  180.92
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PEN ] has closed above bottom band by 8.8%. Bollinger Bands are 23.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 196.71 - 198.01 198.01 - 199.19
Low: 187.74 - 189.4 189.4 - 190.9
Close: 191.1 - 193.71 193.71 - 196.07
Company Description

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Headline News

Mon, 27 May 2024
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for - Yahoo Singapore News

Sun, 26 May 2024
Bull of the Day: Penumbra (PEN) - Yahoo Movies UK

Sun, 26 May 2024
Robeco Institutional Asset Management B.V. Has $133000 Stock Position in Penumbra, Inc. (NYSE:PEN) - Defense World

Sun, 26 May 2024
Should Weakness in Penumbra, Inc.'s (NYSE:PEN) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - Simply Wall St

Sun, 26 May 2024
Trexquant Investment LP Invests $2.53 Million in Penumbra, Inc. (NYSE:PEN) - Defense World

Sun, 26 May 2024
Norges Bank Takes $85.22 Million Position in Penumbra, Inc. (NYSE:PEN) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 39 (M)
Shares Float 37 (M)
Held by Insiders 3.8 (%)
Held by Institutions 90.3 (%)
Shares Short 2,130 (K)
Shares Short P.Month 1,930 (K)
Stock Financials
EPS 2.38
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 31.04
Profit Margin 8.5 %
Operating Margin 4.3 %
Return on Assets (ttm) 4 %
Return on Equity (ttm) 8.3 %
Qtrly Rev. Growth 15.3 %
Gross Profit (p.s.) 0
Sales Per Share 28.37
EBITDA (p.s.) 3.14
Qtrly Earnings Growth 27.2 %
Operating Cash Flow 123 (M)
Levered Free Cash Flow 91 (M)
Stock Valuations
PE Ratio 81.36
PEG Ratio 0.3
Price to Book value 6.23
Price to Sales 6.82
Price to Cash Flow 61.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android